

**Provisional Draft Agenda**  
**69<sup>th</sup> meeting of the Committee for Risk Assessment**  
**(RAC-69)**  
**3-6 June 2024**

**Face-to-face/Hybrid meeting\***

**Monday, 3 June starts at 10.00**  
**Thursday, 6 June ends at 18.15**

***Times are Helsinki times***

**Item 1 – Welcome and Apologies**

**Item 2 – Adoption of the Agenda**

***RAC/A/69/2024***

***For adoption***

**Item 3 – Declarations of conflicts of interest to the Agenda**

**Item 4 – Appointment of (co-)rapporteurs**

4.1 Appointment of (co-)rapporteurs for CLH dossiers, restriction dossiers, authorisation applications, evaluation of occupational exposure limits

***For agreement***

***Closed session***

**Item 5 – Work plan and General RAC procedures**

5 Report on RAC related activities and RAC Work Plan for all processes

***For information***

5.2. General RAC procedures

a) RAC Rules of Procedure (tbc)

***Doc to be distributed***

***For information and agreement***

b) Update on potential new tasks for the committees

---

\*RAC members are expected to participate physically in the meeting. Regular RAC stakeholders may participate either physically or remotely. Occasional stakeholders, all stakeholder experts and dossier submitters are expected to participate remotely.

- c) Good practices in RAC & SEAC opinion-making

**For information and discussion**  
**Joint RAC and SEAC session**

**Item 6 – Requests under Article 77(3)(c)**

*To be determined.*

**For adoption**

**Item 7 – Health based exposure limits at the workplace**

**7.1 Opinions for discussion**

1. 4,4-Isopropylidenediphenol (Bisphenol A) (EC number: 201-245-8; CAS RN: 80-05-7)

**For discussion**

**7.2 Opinions for adoption**

1. 1,3-Butadiene (EC number: 203-450-8; CAS RN: 106-99-0)
2. Boron and its compounds (EC numbers: 233-139-2, 215-575-5, 215-540-4, 215-125-8 and CAS RN: 10043-35-3, 1332-77-0, 1330-43-4, 1303-86-2 respectively)

**For discussion and adoption**

**Item 8 – Harmonised classification and labelling (CLH)**

**8.1 General CLH issues**

1. Report from the April CLH Working Group

**For information**  
**Doc to be distributed**

**8.2 CLH dossiers**

**1. Hazard classes for agreement without plenary debate (A-list)**

- **2,2',6,6'-tetra-tert-butyl-4,4'-methylenediphenol:** *aquatic toxicity*
- **Trihydrogen pentapotassium di(peroxomonosulfate) di(sulfate):** *physical hazards, acute toxicity via all routes, skin corrosion/irritation, eye damage/eye irritation, skin sensitisation, respiratory sensitisation, mutagenicity, carcinogenicity, sexual function and fertility, effect on or via lactation, STOT SE, STOT RE, aquatic toxicity, hazardous to the Ozone layer*
- **Piperonal; 1,3-benzodioxole-5-carbaldehyde:** *skin sensitisation, effect on or via lactation*

*\*RAC members are expected to participate physically in the meeting. Regular RAC stakeholders may participate either physically or remotely. Occasional stakeholders, all stakeholder experts and dossier submitters are expected to participate remotely.*

- **N-1,3-dimethylbutyl-N'-phenyl-p-phenylenediamine:** acute toxicity, skin sensitisation, effect on or via lactation, STOT RE, aquatic toxicity
- **Thymol; 5-methyl-2-(propan-2-yl)phenol:** physical hazards, acute toxicity via all routes, serious eye damage/eye irritation, skin corrosion/irritation, skin sensitisation, mutagenicity, carcinogenicity, reproductive toxicity, aspiration hazard, aquatic toxicity, hazardous to the Ozone layer
- **Bronopol; 2-bromo-2-nitropropane-1,3-diol:** physical hazards, acute toxicity via all routes, serious eye damage/eye irritation, skin corrosion/irritation, skin sensitisation, STOT SE, STOT RE, mutagenicity, carcinogenicity, sexual function and fertility, effect on or via lactation, aquatic toxicity
- **Talc (Mg<sub>3</sub>H<sub>2</sub>(SiO<sub>3</sub>)<sub>4</sub>):** STOT RE
- **4,4'-methylenediphenol; bisphenol F:** reproductive toxicity – development, effect on or via lactation

## 2. Hazard classes for agreement with plenary debate

- 1.1 **Piperonal; 1,3-benzodioxole-5-carbaldehyde** (EC 204-409-7; CAS 120-57-0): reproductive toxicity – fertility and development
- 1.2 **Talc (Mg<sub>3</sub>H<sub>2</sub>(SiO<sub>3</sub>)<sub>4</sub>)** (EC 238-877-9; CAS 14807-96-6): carcinogenicity
- 1.3 **N-1,3-dimethylbutyl-N'-phenyl-p-phenylenediamine** (EC 212-344-0; CAS 793-24-8): reproductive toxicity – fertility and development
- 1.4 **Thymol; 5-methyl-2-(propan-2-yl)phenol** (EC 201-944-8; CAS 89-83-8): STOT SE and STOT RE
- 1.5 **4,4'-methylenediphenol; bisphenol F** (EC 210-658-2, CAS 620-92-8): reproductive toxicity – fertility
- 1.6. **Bronopol; 2-bromo-2-nitropropane-1,3-diol** (EC 200-143-0, CAS 52-51-7): reproductive toxicity – development

**For discussion and adoption**

### Item 9 – Restrictions

#### 9.1 General restriction issues

1. Report from the May REST Working Group
2. Review of the Conformity Check procedure

**For information**

#### 9.2 Restriction Annex XV dossiers

1. Opinion development
  1. Universal per- and polyfluoroalkyl substances (UPFAS) – Draft opinion with focus on hazards (cont.), metal plating and manufacture of metal products, and pending issues from the RAC-68 plenary (consumer mixtures, cosmetics and ski wax)

*\*RAC members are expected to participate physically in the meeting. Regular RAC stakeholders may participate either physically or remotely. Occasional stakeholders, all stakeholder experts and dossier submitters are expected to participate remotely.*

**Item 10 – Authorisation**

**10.1 General authorisation issues**

1. Report from the May AFA Working Group

***For information  
Doc to be distributed***

2. Update on incoming/future applications and horizontal issues

***For discussion/agreement  
Doc to be distributed***

**10.2 Authorisation applications**

**1. Discussion on key issues**

1. 354\_RR1\_CT\_Airbus (2 uses)
2. 355\_RR1\_SD\_Airbus (1 use)
3. 356\_RR1\_SD\_AD-International (1 use)
4. 357\_RR1\_PD\_Lynred (1 use)
5. 358\_RR1\_AsA\_Circuit (1 use)
6. 359\_RR1\_CT\_Circuit (1 use)
7. 360\_DOTE\_Galata (3 uses)
8. 361\_TEL\_Trafigura (1 use)
9. 362\_TEL\_Warter-Fuels (1 use)
10. 363\_CT\_Indestructible\_Paint\_Turbines (1 use)

***For information***

**2. Discussion on key issues**

1. 364\_CT\_CTACSub2 (12 uses)

***For information***

**10.3 Agreement on draft opinions**

**1. Draft opinions for agreement without plenary debate (A-list)**

*To be determined.*

***For agreement***

**2. Draft opinions for agreement with plenary debate**

1. 348\_RR1\_NPE\_Chemetall (2 uses)
2. 349\_RR1\_OPE\_Biomerieux (1 use)
3. 350\_RR1\_OPE\_PPG (2 uses)
4. 351\_PD\_Turdus (1 use)

*\*RAC members are expected to participate physically in the meeting. Regular RAC stakeholders may participate either physically or remotely. Occasional stakeholders, all stakeholder experts and dossier submitters are expected to participate remotely.*

5. 352\_DEHP\_Baxter (3 uses)
6. 353\_TEL\_Shell (1 use)

***For discussion and agreement***

#### **10.4 Adoption of opinions**

1. 302\_CT\_Thoma\_Metallveredelung (1 use)
2. 312\_CT\_Metalplast (Use 1 only)
3. 321\_CT\_LMC (1 use)

***For discussion and adoption***

#### **Item 11 – Drinking Water Directive**

11.3 Update on the DWD related issues (tbd)

***For information/discussion***

#### **Item 12 – AOB**

#### **Item 13 – Minutes of RAC-68**

1. Table with Summary Record of the Proceedings, and Conclusions and Action points from RAC-69

***For adoption***

*\*RAC members are expected to participate physically in the meeting. Regular RAC stakeholders may participate either physically or remotely. Occasional stakeholders, all stakeholder experts and dossier submitters are expected to participate remotely.*

## PROVISIONAL TIMELINE FOR THE DISCUSSIONS AT RAC-69

Please note that timings are approximate. Changes may be made by the Chair before and during the meeting in order to accommodate the discussions.

***Times are Helsinki times***

### **Monday 3 June 2024: Morning session**

10:00	10:10	ADMIN	Welcome and apologies
10:10	10:20	ADMIN	Adoption of the agenda
10:20	10:30	ADMIN	Declarations of conflicts of interest to the Agenda
10:30	10:40	ADMIN	Report on RAC-68 action points, written procedures and update on other ECHA bodies
10:40	11:10	OEL	4,4-Isopropylidenediphenol (Bisphenol A) - presentation
11:10	11:40		<i>Coffee break</i>
11:40	13:10	OEL	1,3-Butadiene - opinion adoption
13:10	14:10		<i>Lunch</i>

### **Monday 3 June 2024: Afternoon session**

14:10	16:10	OEL	Compounds releasing boric acid - opinion adoption
16:10	16:40		<i>Coffee break</i>
16:40	17:00	AOB	Commission roadmap on phasing out animal testing (tbc)

### **Tuesday 4 June 2024: Morning session**

09:30	09:40	CLH	Report from the April CLH Working Group
09:40	10:00	CLH	Hazard classes for agreement without plenary debate (A-list): - Based on RAC members' comments - Based on the RAC WG CLH outcome
10:00	10:20	CLH	Information by Legal on Court cases
10:20	10:40	CLH	Piperonal; 1,3-benzodioxole-5-carbaldehyde
10:40	11:00	CLH	Thymol; 5-methyl-2-(propan-2-yl)phenol
11:00	11:30		<i>Coffee break</i>
11:30	13:00	CLH	Talc ( $Mg_3H_2(SiO_3)_4$ )
13:00	14:00		<i>Lunch</i>

### **Tuesday 4 June 2024: Afternoon session**

14:00	14:20	CLH	4,4'-methylenediphenol; bisphenol F
14:20	14:40	CLH	Bronopol; 2-bromo-2-nitropropane-1,3-diol
14:40	15:00	CLH	<i>N</i> -1,3-dimethylbutyl- <i>N'</i> -phenyl- <i>p</i> -phenylenediamine
15:00	15:30		<i>Coffee break</i>
15:30	17:30	AFA/RESTR	<b>Joint RAC and SEAC session</b> 1. Update on potential new tasks for the committees2. Good practices in RAC and SEAC opinion-making

### ***JOINT RAC AND SEAC PICNIC***

### **Wednesday 5 June 2024: Morning session**

09:30	11:00	RESTR	Universal per- and polyfluoroalkyl substances (U-PFAS): Draft opinion with focus on hazards (cont.)
11:00	11:30		<i>Coffee break</i>

*\*RAC members are expected to participate physically in the meeting. Regular RAC stakeholders may participate either physically or remotely. Occasional stakeholders, all stakeholder experts and dossier submitters are expected to participate remotely.*

11:30	12:00	RESTR	Universal per- and polyfluoroalkyl substances (U-PFAS): Draft opinion with focus on hazards (cont.) <b>contd.</b>
12:00	13:00	RESTR	Universal per- and polyfluoroalkyl substances (U-PFAS): metal plating and manufacture of metal products
13:00	14:00		<i>Lunch</i>

### **Wednesday 5 June 2024: Afternoon session**

14:00	15:30	RESTR	Universal per- and polyfluoroalkyl substances (U-PFAS): metal plating and manufacture of metal products <b>contd.</b>
15:30	16:00		<i>Coffee break</i>
16:00	17:30	RESTR	Universal per- and polyfluoroalkyl substances (U-PFAS): pending issues from the RAC-68 plenary (consumer mixtures, cosmetics and ski wax)

### **Thursday 6 June 2024: Morning session**

09:30	09:45	AFA	AFA general issue: - Update on incoming/future applications and horizontal issues
09:45	09:55	AFA	Report from the May AfA Working Group
09:55	10:20	AFA	A-list agreement on AFAs
10:20	10:30	AFA	302_CT_Thoma_Metallveredelung, 312_CT_Metalplast, 321_CT_LMC - adoption of opinions
10:30	11:00	AFA	AFA segment I
11:00	11:30		<i>Coffee break</i>
11:30	13:00	AFA	AFA segment II
13:00	14:00		<i>Lunch</i>

### **Thursday 6 June 2024: Afternoon session**

14:00	15:00	AFA	AFA segment III	
15:00	15:20	AOB	Presentation by the European Commission DG GROW	
15:20	16:00	AFA	354_RR1_CT_Airbus, 355_RR1_SD_Airbus, 356_RR1_SD_AD-International, 357_RR1_PD_Lynred, 358_RR1_AsA_Circuit, 359_RR1_CT_Circuit, 360_DOTE_Galata, 361_TEL_Trafigura, 362_TEL_Warter- Fuels, 363_CT_Indestructible_Paint_Turbines - key issues discussion	
16:00	16:30		<i>Coffee break</i>	
16:30	17:10	AFA	364_CT_CTACSub2 - key issues discussion	
17:10	17:25	DWD	Update on DWD	
17:25	17:45	AOB	Any other business	
17:45	18:00	ADMIN	Appointment of (co-)rapporteurs for CLH dossiers, restriction dossiers, authorisation applications, evaluation of occupational exposure limits <b>Closed session</b>	
18:00	18:15	ADMIN	Adoption of the RAC-69 report and closure of the meeting	0:15

### ***END OF THE PLENARY***

*\*RAC members are expected to participate physically in the meeting. Regular RAC stakeholders may participate either physically or remotely. Occasional stakeholders, all stakeholder experts and dossier submitters are expected to participate remotely.*